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Abstract  Cell culture is one of the critical bioprocessing steps required to 
generate sufficient human-derived cellular material for most cell-based 
therapeutic applications in regenerative medicine. Automated cell expansion is 
fundamental to the development of scaled, robust and cost effective commercial 
production processes for cell-based therapeutic products. This paper describes the 
first application of process capability analysis to establish and compare the short-
term process capability of manual and automated processes for the in vitro 
expansion of a selected anchorage-dependent cell line. Estimates of the process 
capability indices (Cp, Cpk) have been used to assess the ability of both processes 
to consistently meet the requirements for a selected productivity output and to 
direct process improvement activities. Point estimates of Cp and Cpk show that 
the manual process has poor capability (Cp=0.55, Cpk=0.26) compared to the 
automated process (Cp=1.32, Cpk=0.25), resulting from excess variability. 
Comparison of point estimates, which shows that Cpk < Cp, indicates that the 
automated process mean was off-centre and that intervention is required to adjust 
the location of the process mean. A process improvement strategy involving an 
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adjustment to the automated process settings has demonstrated in principle that 
the process mean can be shifted closer to the centre of the specification to achieve 
an estimated 7-fold improvement in process performance. In practice, the 90% 
confidence bound estimate of Cp (Cp=0.90) indicates that that once the process is 
centred within the specification, a further reduction of process variation is 
required to attain an automated process with the desired minimum capability 
requirement. 
Keywords  Process capability analysis, process transfer, continuous quality 
improvement, automated cell culture, regenerative medicine, tissue engineering, 
cell based therapy. 
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Introduction 
Regenerative medicine is a rapidly developing field that uses human cells or cell-
based constructs as therapeutic products for a broad spectrum of clinical 
applications, predominantly aimed at degenerative conditions, organ failure, and 
tissue damage. Since the 1980’s, research has significantly advanced the science 
of cell and tissue engineering research within the field of regenerative medicine 
but until recently there has been little focus on translation of this science from the 
laboratory bench into clinically and economically viable products (Mason and 
Hoare 2007; Mason and Dunnill 2008a). Growing efforts to commercialise these 
therapies are driving a need for scalable and robust manufacturing technologies to 
ensure these therapies are able to meet regulatory requirements, are economically 
viable at industrial scale production and are affordable (US Food and Drug 
Administration (USFDA) 1997; Directive 2004/23/EC; Williams and Sebastine 
2005; British Standards Institute (BSI) 2006; Department of Trade and Industry 
(DTI) 2006; Commission Directive 2006/17/EC; Commission Directive 
2006/86/EC; Advanced Therapy Medicinal Products (ATMP) Regulation 
1394/2007; Mason and Dunnill 2008b; Lysaught et al. 2008).  
The heterogeneity of human cell based medical products, in terms of 
complexity and the origin and type of cells, makes each manufacturing process 
unique. Moreover, the bioprocessing framework is distinctive because it involves 
critical steps for harvesting cells from the donor or patient, through cell expansion 
and tissue formation to the final step of implantation of the cell based product into 
the patient. Unlike biopharmaceutical product bioprocessing, the status of the 
living human cell is critical throughout all stages of the bioprocess for cell based 
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products, making product consistency at least an order of magnitude more 
difficult to achieve from a bioengineering viewpoint (Mason and Hoare 2007; 
Kemp 2006). In practice, cell sources harvested from donors or patients are 
limited in quantity and therefore cell culture and population expansion is one of 
the critical bioprocessing steps required to generate sufficient cells (e.g. from 5.0 
x 107 to 5.0 x 109 cells) for most cell therapeutic or tissue engineering applications 
(Palsson and Bhatia 2004). Current cell expansion approaches mainly involve 
laboratory-centred, labour intensive manual processes that require highly skilled 
personnel to perform meticulous aseptic manipulations over many days or even 
weeks. For most intended therapeutic applications, these manual processes lack 
the standardisation and reproducibility required for scaled, robust and cost 
effective commercial and regulatory compliant production (Vacanti 2006; Mason 
and Hoare 2007) . Many new developments in robot platforms and sensor 
technology however, are now making it possible to automate production processes 
for scaled-out and/or scaled-up approaches to expanding cell populations 
reproducibly and on a scale suitable for autologous or allogeneic cell based 
therapy. (Archer and Williams 2005; Kempner and Felder 2002; Thomas et al. 
2008a). Several groups, including our own, have attempted to integrate 
automation into various aspects of human cell culture to address the issues of 
process scalability and reproducibility inherent in manual techniques but few have 
sought to use these platforms to evaluate process stability and capability (Kino-
Oka et al. 2005; Joannides et al. 2006; Terstegge et al. 2007; Thomas et al. 2007 
and 2009).  
With growing expectations from regulatory agencies, better process 
understanding and control are likely to be key drivers in the manufacture of 
emerging cell-based products in order to minimise product quality variation, non-
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conformance and delays in product approval (BSI 2006, Vacanti 2006; Archer and 
Williams 2005; USFDA 2004a). As part of an early stage process transfer and 
continuous quality improvement programme, we have adopted a systematic 
approach to evaluate and compare the short-term stability and inherent variability 
of an existing manual process and a fully automated prototype process for the 
serial in vitro expansion of a selected anchorage-dependent cell line. We selected 
a permanent, transformed cell line (human osteocarcoma) as a model system to 
minimise process input variation from cell heterogeneity and allow a direct 
comparison of the cell expansion processes. Process capability analysis is applied 
to reliably assess and compare the behaviour of the processes in the state of 
statistical control. Estimates of the process capability indices, Cp and Cpk, are 
used to relate the process capability to the product requirements for a selected 
performance characteristic of both processes (cell yield) and provide a numerical 
measure of process robustness and production efficiency (American Society for 
Testing and Materials (ASTM) 2008). This analysis of process capability aims to 
improve understanding of the process and provide a scientific basis for 
determining the requirement for process adjustments that can result in process 
improvement in order to allow us to better specify and improve the potential 
quality performance of the automated system, its processes and its parts.   
 
Materials and methods  
General Culture Conditions  
An anchorage dependent human Caucasian osteosarcoma (HOS) cell line was 
used in this study (Lot 01/J/066, European Collection of Cell Cultures (ECACC)). 
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The HOS cells were cryopreserved, according to an established Standard 
Operating Procedure (SOP) and a master and working cell bank established to 
service the entire study (SOP031 2008). Cryopreserved cells recovered from the 
working cell bank were thawed according to an established SOP (SOP032 2008). 
The culture of HOS cells was conducted in 175-cm2 T-flasks (T175 Nunclon, 
Nalgene Nunc, UK) using Dulbecco’s modified Eagle’s Medium (DMEM, Lonza, 
UK) supplemented with 2mM L-glutamine (Sigma-Aldrich, UK), 1% Non-
Essential Amino Acids (NEAA) (Sigma-Aldrich, UK) and 10% Foetal Bovine 
Serum (Lonza, UK). The in vitro expansion of the HOS cell line was conducted in 
parallel monolayer cultures using both manual and automated protocols. A 
seeding density of 7 x 105 cells/flask was used to achieve 70-80% confluence (i.e. 
the percentage of flask surface covered by cells) after 3 days of culture at 37oC 
under an atmosphere of 5% CO2 (v/v) and relative humidity of about 95%. Cells 
were continuously cultured for 9 days to achieve a nominal process target of 1 x 
108 cells. In order to keep cells at a sufficiently low density to stimulate growth, 
cells were passaged on day 3, day 6 and day 9. At each passage, spent medium 
was aspirated and cells detached from the bottom of the flask by exposure to a 
trypsin-EDTA (Sigma-Aldrich) solution (10 ml at 0.25% w/v) at 37oC, 5% CO2 
(v/v) for 7 minutes. Flasks were split at a ratio of 1 to 4 after each passage. 
Manual and automated processes were carried out according to established SOPs 
(SOP012 2008; SOP043 2008) and maintained according to the guidance for good 
cell culture practice (Coecke et al. 2005). All final cell suspensions obtained from 
both automated and manual culture processes were tested and found negative for 
the presence of mycoplasma (Mycoplasma Experience Ltd, UK). 
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Instrumentation 
The CompacT SelecT (The Automation Partnership, UK) is a fully automated cell 
culture platform which incorporates a small 6-axis anthropomorphic robotic arm 
that can access 90 x T175 flask and plate incubators, controlled at 37oC under an 
atmosphere of 5% CO2 (v/v) and relative humidity of about 95%. Flasks are bar-
coded for identification and cell process tracking. Two flask decappers and flask 
holders, automated medium pumping and an automatic cell counter (Cedex®, 
Roche Innovatis AG, Germany) are integrated within a High Efficiency 
Particulate Air (HEPA) filtered cabinet to ensure sterility. The system allows the 
automation of seeding, feeding and other cell culture processes in order to 
maintain cell lines in standard T175 cell culture flasks (Figure 1). 
 
INSERT FIGURE 1 
Manual HOS cell culture and passage protocol 
Cells recovered from cryopreservation were seeded into one T175 flask. Once 
cells had attached to the bottom of the flask after 4 hours culture, the medium was 
replaced with fresh medium to remove cryoprotectant agents. After each passage, 
the cell suspension was centrifuged to remove the residual trypsin-EDTA. The 
collected cells were re-suspended in fresh medium and the concentration of viable 
cells for subsequent seeding determined by the trypan blue exclusion test on a 
haemocytometer under an optical microscope (Figure 1). On day 9, the cell 
suspension from each flask was pooled into one flask (nominally the production 
unit or lot), mixed by gentle swirling and the final concentration of viable cells 
measured by the trypan blue exclusion test to determine the total number of cells 
recovered (Figure 1).  
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Automated HOS culture and passage protocol using the CompacT 
SelecT 
Previous studies by the authors have established the successful transfer of an 
existing manual HOS culture protocol to the fully automated culture process. The 
automated culture of HOS cells was developed to replicate the volume dependent 
(seeding volume, medium volume etc) and volume independent (seeding density, 
pH, temperature, mixing etc) operating conditions of the manual culture process 
as closely as possible. However, because the CompacT SelecT has no 
centrifugation capability, after each passage flasks were removed from the 
incubator and fresh medium pumped into the flask to neutralise and dilute the 
trypsin-EDTA. The cell suspension was mixed and a 1ml sample pipetted into the 
integrated Cedex® cell counter. After 9 days culture, the cell suspension from 
each flask was pooled into 1 flask (nominally the production unit or lot), mixed by 
repeat pipetting and the final concentration of viable cells measured by Cedex®, 
which uses the trypan blue exclusion test and automated digital image recognition 
to determine the total number of cells recovered (Figure 1).  
 
Experimental Framework 
A previous measurement system analysis, comprising an established Gauge 
Repeatability & Reproducibility (Gauge R&R) methodology, verified that both 
the manual and automated measurement systems utilised to determine viable cell 
number introduce minor measurement error or bias and were capable of detecting 
product variation (Liu et al. 2007).  
Study 1: Serial culture runs, involving the in vitro expansion of the 
anchorage-dependent HOS cell line, were conducted in parallel using both manual 
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and automated (CompacT SelecT) protocols. Each process was used to generate 
10 full-scale production units or lots of cells under operating conditions that were 
as identical as possible. The production units were generated over a 14 month 
‘long run’ period so that substantial sources of variation in the response output 
could be captured, although some sources of variation were held constant i.e. 
selected key process operating parameters, such as seeding density, critical raw 
material, ancillary components and consumable batches. All process parameters 
were recorded in a Manufacturing Batch Record (MBR) for each production run 
to monitor deviations from the SOPs and ‘out of specification’ observations.  
The process yields (total cell number of viable cells) recovered from the 
10 production units or lots of cells generated from each of the manual and 
automated culture processes were used to calculate capability statistics and allow 
comparison of processes (ASTM 2008). To evaluate capability indices (Cpk, Cp), 
nominal design specifications for cell yield were generated based on a clinical and 
experimental rationale. The nominal lower specification limit, based on a putative 
minimum therapeutic requirement (Palsson and Bhatia 2004), was set to 5.0 x 107 
cells and the nominal upper specification limit, based on the requirement to 
control over-confluence and its affect on cell state and other quality parameters, 
was set to 1.5 x 108 cells. The specification was applied to both processes in the 
same way to allow process comparison to be explored.  
Study 2: A second study was carried out using an alternative automated 
process in which the settings of the passage process were adjusted in order to 
minimise the potential adverse effects of residual trypsin-EDTA on the processing 
of cells (based on a Cause and Effect analysis of the baseline automated process 
shown in Figure 2). The automated process was carried out as before except for 
the following: After each culture incubation, spent medium was removed from the 
Page 9 of 35
http://mc.manuscriptcentral.com/term
Journal of Tissue Engineering and Regenerative Medicine
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
For Peer Review
10 
flask and the cells washed with 30 ml of phosphate buffered saline (PBS) in order 
to remove any residual serum (from the medium). At each passage, a solution of 
0.25% trypsin-EDTA (15 ml) was pumped into the flask, the flask swirled for 20 
seconds to ensure an even coverage of enzyme across the cell sheet, and then the 
excess removed from the flasks. After 10 minutes at 37oC, 5% CO2 (v/v), the 
flasks were removed from the incubator and fresh medium pumped into the flask 
to neutralise and dilute the trypsin-EDTA. After 9 days culture, the cell 
suspension from each flask was pooled into 1 flask (nominally the production unit 
or lot), and the final concentration of viable cells measured as before. 
Three full-scale production units or lots of HOS cells were generated using 
the automated protocol with adjusted process settings. The data for this short 
verification run was acquired over a 1 month period. All process runs were carried 
out using process operating conditions that were as identical as possible to those 
used in Study 1.  
 
INSERT FIGURE 2 
Statistical analysis: 
Process capability and statistical control parameters were evaluated using Minitab 
v15 software (Minitab Ltd, UK). It was not feasible to group measurements into 
subgroups because long cycle times (9 days) and operational expense limited the 
production volume to a small run of one product unit per process run. Process 
capability indices and control charts were therefore calculated using a sample 
consisting of individual observations. The individual observations (total cell 
number for each production unit) were plotted on an individuals moving range 
chart (I-MR chart) to assess whether the process was in statistical control and 
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estimate process standard deviation. Control charts were subjected to a set of 
decision rules based on probability theory and supported by Minitab, to detect 
non-random patterns in the data and the occurrence of special causes (ASTM 
2008; Nelson 1984; Montgomery 2005). Normal probability plots were used to 
confirm the data were normally distributed. The Anderson-Darling test (AD) was 
used to compare the empirical cumulative distribution function of the sample data 
with the distribution expected if the data were normal. A p-value of <0.05 was 
considered significant for tests of normality. The Cp index was calculated 
according to the following equation: 
σ6
LSLUSLCp −= . The Cpk index was 
calculated according to the following equation; Cpk 

−


 −=
σ
µ
σ
µ
3
,
3
min LSLUSL ; 
where USL is the upper specification limit, LSL is the lower specification limit, σ 
is the estimated process standard deviation, µ is the process mean (ASTM 2008). 
Lower 90% confidence bounds were calculated for all capability estimates 
(smallest value for the process index that can be claimed with a stated confidence 
of 90%) (ASTM 2008). Cell yields were expressed as process mean +/- Standard 
error of the mean (SEM) and a Students t-test used to compare the cell population 
mean output.    
Results 
Study 1: The cell population growth (total number of cells) in the manual culture 
reached an average of 1.3 x 108 cells after 3 passages (9 days), which was close to 
the expected target of 1.0 x 108 (based on a calculated doubling time of 20-24 hrs) 
and more than twice the cell growth achieved by the automated culture process 
(average of 6.0 x 107 cells) (Table 1). Images of the HOS cells cultured by the 
manual or automated culture protocols showed that they appeared healthy post-
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passage and were morphologically similar (Figure 3). The viability data 
(determined by Trypan blue exclusion both by the Cedex® instrument in the 
CompacT SelecT and manually) for the cultured HOS cells indicated that neither 
process had an effect on cell survival. The mean live cell population in the 
‘granddaughter’ flasks after 3 passages was 98% in the manual process and 95% 
in the automated process. 
 
INSERT TABLE 1 
INSERT FIGURE 3 
 
Analysis of the I-MR control charts and histograms for the individual 
observations (Figure 4) showed that both the manual and automated processes 
were in statistical control over the course of the study (i.e. observations varied 
randomly around the centre line between the control limits and exhibited no trends 
or patterns in the plotted points) and that the data was normally distributed (i.e. 
normal probability plots showed that plotted points were close to a straight line 
and within the 95% confidence interval for both the manual (AD = 0.429; 
p<0.245) and automated (AD = 0.188; p<0.870) process data). This confirmed the 
validity of the data and satisfied the assumptions critical for the reliable estimation 
and interpretation of the process capability indices according to the ASTM 
standard guideline (ASTM 2008). 
 
INSERT FIGURE 4 
 
The behaviour of the process in the state of statistical control (indicating 
consistency of process output) was used to reliably describe its capability in terms 
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of the proportion of the process output that is within the product specifications. 
Two short-term capability indices (Cp, Cpk) were calculated to provide a 
numerical summary that relates the process spread (the 6-σ variation) to the 
specification spread (Cp) and also considers the location of the process mean 
within the specification limits (Cpk) (ASTM 2008). Collectively, the Cp and Cpk 
indices were used to indicate the potential of the process to produce conforming 
material and to signal the requirement for process location adjustments and/or 
process variation reduction (ASTM 2008). 
The process mean for the manual cell culture process (1.3 x 108 cells) was 
located close to the centre of the nominal specification, but the capability 
histogram (upper panel of Figure 5) for the manual process data showed poor 
potential capability (Cp <1.0) resulting from excess variability. The process mean 
for the automated cell culture process (6.0 x 107 cells) was poorly located within 
the nominal specification limit, but the capability histogram (middle panel of 
Figure 5) showed that the automated process performed with less variability than 
the manual process, resulting in adequate potential capability (Cp>1.0). 
Comparison of the point estimates for the Cp indices indicated that, relative to the 
specification limits, the automated process (Cp=1.32) could achieve better 
capability than the manual process (Cp=0.55) if the process can be centred.  
 
INSERT FIGURE 5 
 
The point estimate for the Cpk index of the automated process (Cpk=0.25) was 
lower than its corresponding Cp index (Cp=1.32). Comparison of the point 
estimates (Cp>1.0, Cpk<1.0), indicated that the automated process is capable, but 
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not centred and not performing within the specification limits  The point estimate 
for the Cpk index of the manual process (Cpk=0.26) was also lower than its 
corresponding Cp index (Cp=0.55). Comparison of the point estimates (Cp<1.0, 
Cpk<1.0), indicated that the manual process is not capable and not performing 
within the specification limits (ASTM 2008). 
The Cpk indices of <1.00, indicated that a substantial part of the output of 
both processes falls outside the specification limit. Figure 5 shows that the Cpk 
indices for both processes were similar but had differing proportions of 
conforming units (proportion of the specification used by the process). 
Comparison of the CpL and CpU values (Figure 5) indicated that the process 
distribution is located closer to the lower specification limit for the automated 
process (CpL<CpU; Cpk=CpL) and closer to the higher specification limit for the 
manual process (CpL>CpU; Cpk=CpU). Analysis of the histograms showed that 
about 23% of the process output falls outside the lower specification limit  for the 
automated process (equivalent to a predicted fall out of about 225,000 non-
conforming parts per million (ppm)). For the manual process, about 21% was 
shown to fall outside the higher specification (predicted fall out of about 214,000 
non-conforming ppm) but a small proportion (about 1%) also falls outside the 
lower specification (predicted fall out of about 6620 non-conforming ppm). 
Study 2: Differences in cell population growth profile were observed 
between the automated and manual protocols in study 1 (Table 1). After 
implementing the adjustment to the automated passage process, a short 
verification run of 3 production units was conducted to demonstrate an affect on 
process performance. Results showed that the new passage protocol was effective 
for detaching cells from the surface of the flask and forming a single cell 
suspension at the end of the treatment. Images of the HOS cells cultured by the 
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adjusted automated culture protocol showed that they appeared healthy post-
passage and were morphologically similar to the cells cultured in both the manual 
and baseline automated processes (Figure 3). The viability data for the cultured 
HOS cells indicated that the process did not affect cell survival. The mean live 
cell population in the ‘granddaughter’ flasks after 3 passages was 95%.  
The cell yield obtained from the adjusted automated process reached an 
average of 7.3 x 107 cells, which was closer to the nominal target of 1.0 x 108 cells 
and more than 1.2 fold (22%) higher than the that of the baseline automated 
process (6.0 x 108 cells), resulting in a shift in the mean process yield closer to 
centre of the specification (Figures 4 & 5). Assuming that the process mean 
adjustment has no effect on process variability (i.e. Cp=1.32), a shift in process 
mean to 7.3 x 107 cells would achieve an estimated Cpk of 0.61 (lower 90% 
confidence bound Cpk= 0.41). This would yield a predicted fallout of the process 
of 34,537 non-conforming ppm, representing about a 7-fold improvement in 
process performance. 
 
Discussion  
The transition to robust, scaled culture and expansion of human cells represents 
one of the most significant bioengineering challenges that need to be met for cell 
based products to become safe, effective and affordable therapeutic modalities of 
regenerative medicine. Automated platforms have the potential to provide the 
operational stability and control to allow the scalable processing and population 
expansion of cells at the volumes required for cell based therapeutic products for 
human use, including products for clinical trials and cell repositories (Palsson and 
Bhatia 2004; Archer and Williams 2005). Previously, we have described the 
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process transfer of a number of bench scale manual cell culture protocols to a 
completely automated cell culture platform (CompacT SelecT); including 
processes for the in vitro expansion of primary bone marrow-derived 
mesenchymal stem cells, primary umbilical cord-derived progenitor cells, and 
human embryonic stem cells (Thomas et al. 2007, 2008a, 2009). Several other 
groups are also beginning to integrate automation into various aspects of human 
cell culture to address the issues inherent in conventional manual techniques 
(Kino-Oka et al. 2005; Joannides et al. 2006; Terstegge et al. 2007). Until now, 
these studies have sought to demonstrate equivalent performance in terms of 
selected mean process output parameters and have not attempted to quantify and 
analyse inherent process variability relative to product specifications or 
requirements, referred to as process capability.  
Process capability analysis approaches have been widely used in mature 
industry sectors such as the electronics, pharmaceutical and medical devices 
sectors, typically within quality-by-design frameworks and continuous quality 
improvement programmes (USFDA 2004b; Yang and Liu 2005; Pearn and Wu 
2005; Liu et al. 2008; Cogdill and Drennen 2008). In accordance with current 
regulatory drivers under Good Manufacturing Practice and the new European 
Union Tissues and Cells Directives (ATMP Regulation 1394/2007/EC), these 
approaches, as part of a quality function early in development, are likely to be 
equally important to gaining better process understanding and control of emerging 
cell based therapy products and their manufacturing processes, particularly to 
minimise product quality variation, non-conformance and delays in product 
approval.  
This study has demonstrated the application of process capability analysis 
to establish and compare the short-term process capability of a manual and a 
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prototype automated culture process for the in vitro expansion of a selected 
anchorage-dependent cell line. The results of the short-term process capability 
analysis indicated that the manual process had poor potential capability (Cp<1.0) 
resulting from excess variability. The automated process was poorly located 
within the specification limits but was less variable than the manual process, 
resulting in a higher potential capability (Cp>1.0). The two processes had similar 
Cpk indices but were centred differently and had differing proportions 
conforming, which shows that the Cpk index only communicates process 
performance relative to one of the two specification limits. Similarly, the Cp value 
alone is not sufficient to communicate the proportion conforming. It is therefore 
necessary to compare values for both Cp and Cpk in order to determine the 
current proportion conforming. A comparison of point estimates, which showed 
Cpk < Cp, indicated that the automated process mean was off-centre and that 
intervention is required to adjust the process location by increasing the process 
mean. If the process mean is centred, Cpk=Cp=1.32, almost all of the process 
measurements fall inside the specification limits, representing an improvement of 
several orders of magnitude in process performance.  
Overall, comparison of the point estimates for the Cp and Cpk indices 
indicated that, relative to the specification limits, the automated process could 
achieve better capability than the manual process if the process mean can be 
shifted closer to the centre of the specification (equivalent to about a 1.7 fold shift 
in process mean). This indicated that intervention is required to adjust the process 
location by increasing the process mean until Cpk=Cp=1.32. Assuming that the 
specification accurately reflects the customer requirement and that the process is 
properly centred with a normal distribution, this process would produce an 
estimated 78 non-conforming ppm (i.e. 39 ppm outside both the LSL and HSL 
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limits), representing an improvement of several orders of magnitude in process 
performance. 
However, in practice point estimates of capability indices are subject to 
sampling error as a function of sample size (ASTM 2008; Montgomery 2005). 
The 90% confidence bound estimate of Cp for the automated process was 
Cp=0.90, which means that for a sample size n=10, we can only be 90% confident 
that the Cp index is not less than or equal to 0.90. Even though the point estimate 
of Cp for the automated process met the minimum requirement (Cp ≥ 1.0) for a 
capable process (Pearn and Chen 1999; Montgomery 2005), the 90% confidence 
bound value (Cp=0.90) suggests that we are unable to conclude with 90% 
confidence that the process meets this minimal requirement. Put another way, to 
be 90% confident that the capability index was ≥1.00, based on a sample size 
n=10 we would need to achieve a capability index of ≥1.5, which is clearly higher 
than the observed point estimate for Cp (Cp=1.32). This indicates that, even with 
an adjustment to the process mean to properly centre the process, intervention is 
required to reduce process variation in order to achieve a minimum acceptable Cp 
≥ 1.0 i.e. the ability to produce more than 99.73% lots within the specification. 
Since the process capability analysis showed that the automated process 
was in control but not capable of meeting specifications without centring, an 
investigation to identify assignable causes for the bias was conducted using 
quality tools such as process mapping and cause and effect (C&E) analysis. The 
C&E matrix shown in Figure 2 was constructed to define and relate the key 
process steps and process input variables to the key outputs (cell yield) using a 
process map as the primary source. The high-level fishbone diagram (Figure 2) 
identifies the sub-processes or process steps, categorised as neutralisation, sub-
culture, pooling and passage, as the main sources of interdependent variation. It 
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was used to identify the relationships among the various parameters (inputs) and 
characteristics (outputs) from implicit knowledge in the first instance (Thomas et 
al. 2007; Thomson 2007). The limbs on the branches record the causes or the 
input variables that could be contributing to the observed effect. 
The differences in process mean output for the manual and automated 
processes can be traced to the observed differences in cell population growth 
profile, attributed to key operational parameter differences between the protocols. 
The similarity in population growth of cells in manual and automated culture up 
to the first passage suggested that the observed difference in subsequent cell 
population growth, culminating in lower cell output in the automated system, may 
be attributable to operational parameter differences introduced at the passage 
point. Despite minor non-linear operating parameter differences from the manual 
process (such as the modes of dispensing and removing medium, mixing cell 
suspensions etc), the most obvious such difference is the absence of a 
centrifugation step to remove residual trypsin from the harvested cell suspension 
before subsequent passage in the automated process. Instead, the automated 
process relies on neutralisation of trypsin through the addition of culture medium 
containing 10% FBS, which is known to contain trypsin inhibitors. Previous 
investigations of trypsin contamination and cell population growth have suggested 
that non-optimised automated passage protocols can result in incomplete 
neutralisation of the trypsin, leaving sufficient residual trypsin (typically 1–4%) to 
inhibit cell adhesion and cell growth and therefore contribute to the differences in 
cell yield observed between automated and manual culture protocols (Cruz et al. 
1997; Thomas et al. 2007). Based on this hypothesis, a short trial verification run, 
comprising three production lots of cells, was manufactured using an alternative 
automated process in which the settings of the passage process were adjusted in 
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order to eliminate residual trypsin activity and any adverse effect on the 
subsequent processing of cells. In practical terms, the adjusted process produced 
on average about 1.2 fold more cells than the baseline automated process, shifting 
the process mean closer to the centre of the specification, and resulting in a 7-fold 
improvement in process performance based on a point estimate of Cpk.  
The results of this short verification run indicated that the trypsinisation 
sub-process may be a critical source of process variability and in principle, 
demonstrates that by making changes to the process settings, the process mean of 
the automated process can be shifted towards the centre of the specification to 
improve the actual capability of the automated process. However, further studies, 
based on statistically designed experiments (DOE), are required to find the 
optimal settings for the cell dissociation (trypsinisation) sub-process variables in 
order to further increase the process mean and reduce the overall process 
variability for long-term improvement (Thomas et al. 2008b).  
Overall, this study demonstrates the potential process capability of an 
automated, scalable system as a platform suitable for the production of anchorage 
dependent cells in sufficient volumes for regenerative medicine applications. The 
need for detailed understanding of processes, process optimisation and process 
standardisation, is highlighted by the observed differences in cell population 
growth profile, attributed to key operational differences between the automated 
and manual protocols. The cell dissociation step in particular has important 
implications for the efficient scale-up and automation of bioprocesses for 
anchorage dependent cells. 
The next phase of our systematic approach will target an improvement 
strategy leveraging key process variables, firstly to centre the automated process 
between the specification limits and then to reduce variation. The implementation 
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of this focus is to create a process with Cp>1, although ultimately the 
improvement target will depend on a company’s quality focus, attitude to risk, 
marketing plan and their competitor position.  
In this study we selected a permanent, transformed cell line (HOS) as a 
model system to compare the short-term process capability manual and automated 
culture processes. Primary cells, such as embryonic stem cells (ESC), are known 
to be more sensitive to process variability than established cell lines and are likely 
to present a greater technical challenge for the scaled production of consistently 
safe, efficacious and genetically stable primary cellular preparations for successful 
applications in Regenerative Medicine.  
Many studies have highlighted the sensitivity of primary cells, such as 
ESC, to variations inherent in manual handling procedures (Thomson 2007; 
Thomas et al. 2007 and 2009; Veraitch et al 2008). These studies also reveal how 
manual protocols for ESC cultivation could be improved by automating critical 
sub-processes to control variation in parameters such as cell density measurement, 
fluid flow, shear forces, pH and temperature. Further systematic process 
development studies will target other more clinically important anchorage-
dependent cell types, aimed at translating features that are critical to quality from 
the perspective of patients to the features that are critical to quality in the 
automated manufacturing process (Mason and Dunnill 2008a and 2008b). The 
accumulated process understanding obtained during these studies will provide 
opportunities for further risk mitigation and allow a framework to be established 
to determine the design space which will define the critical unit control 
parameters that can be varied to consistently produce a cell based product with the 
desired specification.  
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LEGENDS FOR FIGURES AND TABLES 
Figure 1: Comparison of key features of the automated (left panel) and manual 
(right panel) cell culture systems. Specific features of the CompacT SelecT are 
shown. This automated cell culture platform can simultaneously manipulate 2 x 
T175 flasks and house 90 x T175 culture flasks in a robot accessible incubator. 
All culture processes are carried out within a sterile class II environment and 
require no manual intervention. The inset shows an enlarged image of the 
manipulation chamber and pipette head. Major processing components are 
labelled: A, Robot arm (inset); B, Flask incubator; C, Plate incubator; D, Flask 
decappers (inset); E, Flask holders (inset); F, Media pumps; G, Pipette head; H, 
Cedex® automated cell counter. 
Figure 2: Cause-and-effect diagram for investigation of the low average viable 
cell yield obtained using the automated cell culture system. The quality 
improvement team identified potential causes of the problem, categorised within 
the primary sub-processes. Informed by differences between the manual and 
automated culture systems, the most likely causes were identified (indicated by 
open circle symbol). 
Figure 3: A representative selection of images of HOS cells cultured using the 
baseline automated (centre panel) and manual cell expansion (left panel) 
protocols. The right panel shows the images of HOS cells cultured using 
automated process with the adjusted passage protocol settings. Images show cells 
in monolayer culture prior to passage 3. Cells are morphologically similar. 
Figure 4: Plots of individual observations (I chart) and moving ranges (MR chart) 
for variables data from manual (upper panel) and automated (lower panel) culture 
processes. The I-MR chart for the automated process (lower panel)is split into two 
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stages showing the individual observations and moving ranges for the first 10 
production units (Study 1) and for the 3 production units (lots 11-13) generated 
from the adjusted automated protocol (Study 2). Tests for special causes for the 
variation confirmed that all points varied ‘randomly around the centre line and 
were within the control limits.  
Figure 5: Process capability histograms for the manual process data (upper 
panel), automated process data (middle panel) and adjusted automated process 
data (lower panel). Total number of harvested cells (cell yield) is shown on the y-
axis. Dashed vertical lines indicate the lower specification limit (LSL) = 5.0 x 107 
and the upper specification limit (USL) = 1.5 x 108. Solid arrow indicates process 
mean and the solid line represents the normal density function for within variance. 
Process and capability data is displayed in the boxes at the left side of each panel. 
Cp = process capability irrespective of process centring, Cpk = process capability 
accounting for process centring, CpU = process capability relative to the USL, 
CpL = process capability relative to the LSL. 
Table 1: HOS cell population expansion (total number of cells/flask) at each 
passage, for cells grown using the manual and baseline automated culture 
processes (Study 1) and the automated process with adjusted passage protocol 
settings (Study 2). Mean total number cells/flask +/- SEM based on 3 passages for 
each of 10 production runs (Study 1). Mean total number cells/flask +/- SEM 
based on 3 passages for each of 3 production units generated from the adjusted 
automated protocol (Study 2). Automated culture process means significantly 
different (p<0.05) from manual culture process means (two sample t-test) is 
indicated by an asterisk. 
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Table 1 
 
Manual Culture 
Mean cell number/flask 
+/- SEM 
Automated Culture 
Mean cell number/flask 
+/- SEM 
Adjusted Automated Culture 
Mean cell number/flask +/- 
SEM 
Passage 1 (Day 3) 4.6 x 106 +/- 1.3 x 106  3.4 x 106 +/- 1.1 x 106 4.4 x 106 +/- 2.5 x 105  
Passage 2 (Day 6) 8.0 x 106 +/- 2.1 x 106 4.2 x 106 +/- 1.7 x 106* 5.3 x 106 +/- 1.0 x 106 * 
Passage 3 (Day 9) 1.3 x 108 +/- 4.2 x 107 6.0 x 107 +/- 1.6 x 107* 7.3 x 107 +/- 9.0 x 106  
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Figure 1: Comparison of key features of the automated (left panel) and manual (right panel) cell 
culture systems. Specific features of the CompacT SelecT are shown. This automated cell culture 
platform can simultaneously manipulate 2 x T175 flasks and house 90 x T175 culture flasks in a 
robot accessible incubator. All culture processes are carried out within a sterile class II environment 
and require no manual intervention. The inset shows an enlarged image of the manipulation 
chamber and pipette head. Major processing components are labelled: A, Robot arm (inset); B, 
Flask incubator; C, Plate incubator; D, Flask decappers (inset); E, Flask holders (inset); F, Media 
pumps; G, Pipette head; H, Cedex® automated cell counter.  
253x190mm (150 x 150 DPI)  
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Figure 2: Cause-and-effect diagram for investigation of the low average viable cell yield obtained 
using the automated cell culture system. The quality improvement team identified potential causes 
of the problem, categorised within the primary sub-processes. Informed by differences between the 
manual and automated culture systems, the most likely causes were identified (indicated by open 
circle symbol).  
457x305mm (96 x 96 DPI)  
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Figure 3: A representative selection of images of HOS cells cultured using the baseline automated 
(centre panel) and manual cell expansion (left panel) protocols. The right panel shows the images of 
HOS cells cultured using automated process with the adjusted passage protocol settings. Images 
show cells in monolayer culture prior to passage 3. Cells are morphologically similar.  
831x203mm (96 x 96 DPI)  
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Figure 4: Plots of individual observations (I chart) and moving ranges (MR chart) for variables data 
from manual (upper panel) and automated (lower panel) culture processes. The I-MR chart for the 
automated process (lower panel)is split into two stages showing the individual observations and 
moving ranges for the first 10 production units (Study 1) and for the 3 production units (lots 11-13) 
generated from the adjusted automated protocol (Study 2). Tests for special causes for the 
variation confirmed that all points varied ‘randomly around the centre line and were within the 
control limits.  
458x305mm (96 x 96 DPI)  
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Figure 5: Process capability histograms for the manual process data (upper panel), automated 
process data (middle panel) and adjusted automated process data (lower panel). Total number of 
harvested cells (cell yield) is shown on the y-axis. Dashed vertical lines indicate the lower 
specification limit (LSL) = 5.0 x 107 and the upper specification limit (USL) = 1.5 x 108. Solid arrow 
indicates process mean and the solid line represents the normal density function for within variance. 
Process and capability data is displayed in the boxes at the left side of each panel. Cp = process 
capability irrespective of process centring, Cpk = process capability accounting for process centring, 
CpU = process capability relative to the USL, CpL = process capability relative to the LSL.  
760x507mm (96 x 96 DPI)  
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